Intelligence · Patents
Patents expiring in 2035
Annual patent cliff calendar for 2035 — US pharmaceutical patents by expiration date.
- Patents
- 1,447
Quick answer
1,447 indexed pharmaceutical patents have expiration dates in 2035. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8927528
Composition for treating hearing loss
granted -
US 8927016
Producing a sustained-release preparation
granted -
US 8927725
Thio compounds
granted -
US 8927709
Hepatitis C virus inhibitors
granted -
US 8927576
HCV inhibitor and therapeutic agent combinations
granted -
US 8927692
Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
granted -
US 8926986
Use of saccharides cross-reactive with Bacillus anthracis spore glycoprotein as a vaccine against anthrax
granted -
US 8927750
Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
granted -
US 8927564
Synthesis of polycyclic alkaloids
granted -
US 8926965
Nucleic acid encoding superoxide dismutase variants and methods of use thereof
granted -
US 8926966
Cloned glutamic acid decarboxylase
granted -
US 8927557
Methylpyrrolopyrimidinecarboxamides
granted -
US 8926987
Replication-competent adenoviral vectors
granted -
US 8927275
Differentiation of human embryonic and induced pluripotent stem cells
granted -
US 8927269
Avian adenoassociated virus and uses thereof
granted -
US 8927730
Intramolecular hydrogen-bonded nitric oxide synthase inhibitors
granted -
US 8927495
Use of GnRH and analogs thereof for the prevention and treatment of pet ferret adrenocortical hyperplasia
granted -
US 8927573
8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
granted -
US 8927249
Extended soluble PH20 polypeptides and uses thereof
granted -
US 8927233
Fusion polypeptides capable of activating receptors
granted -
US 8927718
Fused heterocyclic ring derivative and use thereof
granted -
US 8927506
Acetates of 2-deoxy monosaccharides with anticancer activity
granted -
US 8926969
Anti-CD38 antibodies
granted -
US 8927215
GNA11 mutations in melanoma
granted -
US 8927030
Use of nitrite salts for the treatment of cardiovascular conditions
granted -
EP 2819679
FLÜSSIGE FORMULIERUNGEN ENTHALTEND HYPOGLYZEMISCHE SULFAMIDE
granted -
US 8932588
Treatment of cancer involving mutated KRAS or BRAF genes
granted -
US 8932846
Unmarked recombinant intracellular pathogen immunogenic compositions expressing high levels of recombinant proteins
granted -
US 8932572
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
granted -
US 8932818
Screening assays for compounds that modulate programmed ribosomal frameshifting
granted -
US 8933047
Poly(acrylate) polymers for in vivo nucleic acid delivery
granted -
US 8933069
Heterocyclic compound
granted -
US 8933111
Crystalline form of (2S,4R)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1H-[1,2,3]triazole-4-carbonyl)-amino]-pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester
granted -
US 8932060
Dental treatment method
granted -
US 8933071
Dimethyl fasudil for inducing polyploidization of megakaryocytes and for treating blood and bone marrow diseases and disorders
granted -
US 8933030
Treatments for gastrointestinal disorders
granted -
US 8933080
Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
granted -
US 8933115
Stabilized statin formulations
granted -
US 8933041
System for treating and preventing breast cancer
granted -
US 8932583
Scaffolds for cell transplantation
granted -
US 8933105
Pyrrole compounds
granted -
US 8932853
Method for manufacturing pancreatic-hormone-producing cells
granted -
US 8933110
Hepatitis C virus inhibitors
granted -
US 8933059
Natural combination hormone replacement formulations and therapies
granted -
US 8932561
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
granted -
US 8933031
Polypeptide inhibiting angiogenesis and application thereof
granted -
US 8933076
Pyridazine compounds, compositions and methods
granted -
US 8933217
Compounds, compositions, and methods for protecting brain health in neurodegenerative disorders
granted
Frequently asked questions
How many pharma patents expire in 2035?
1,447 published patents in our USPTO index have expiration dates falling in calendar year 2035.